Not Yet RecruitingNot Applicable

Kinetics of C-Reactive Protein in Giant Cell Arteritis Following Glucocorticoid Initiation: A Pilot Study (GIDEON)

40 participantsStarted 2026-06-22

Plain-language summary

We propose to analyze the kinetics of the main marker of inflammation in GCA in order to understand its links with initial clinical manifestations and the possible appearance of complications and/or relapses. Early assessment of the rate of CRP normalization would enable us to adapt the therapeutic strategy in order to avoid complications and/or relapses.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients aged 18 or older hospitalized in the internal medicine department with a new diagnosis of ACG * Personne affiliée ou bénéficiaire d'un régime de sécurité sociale * Free and informed consent signed by the participant and the investigator Exclusion Criteria: * Patients scheduled to be placed on a sparing regimen during hospitalization * Patients with renal insufficiency (eGFR ≤ 60 mL/min/1.73 m²) * Patients with a history of corticosteroid-treated pseudopolyarthritis * Patients with ACG and visual impairment (severity criterion) * Patients on immunosuppressants or biologic therapy * HIV infection or progressive malignancy * Known poor treatment adherence * Dementia * Pregnant or breastfeeding women * Patients under legal guardianship

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

CRP testing

Timeframe: 1 year

Trial details

NCT IDNCT07720804

SponsorUniversity Hospital, Limoges

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-06-22

Contact for this trial

Kim LY, Professor

05 55 05 05 05 Kim.Ly@chu-limoges.fr

View on ClinicalTrials.gov More Giant Cell Arteritis (GCA) trials